Peregrine Capital Management LLC Has $6.54 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Peregrine Capital Management LLC increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 28.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 53,804 shares of the biotechnology company’s stock after acquiring an additional 11,965 shares during the quarter. Peregrine Capital Management LLC’s holdings in Sarepta Therapeutics were worth $6,542,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Atria Wealth Solutions Inc. grew its stake in shares of Sarepta Therapeutics by 10.5% in the fourth quarter. Atria Wealth Solutions Inc. now owns 11,692 shares of the biotechnology company’s stock worth $1,422,000 after purchasing an additional 1,108 shares during the last quarter. CIBC Asset Management Inc grew its position in shares of Sarepta Therapeutics by 5.1% in the 4th quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 139 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Sarepta Therapeutics by 5.6% in the fourth quarter. Principal Financial Group Inc. now owns 282,084 shares of the biotechnology company’s stock valued at $34,299,000 after buying an additional 15,047 shares during the period. State of New Jersey Common Pension Fund D raised its position in shares of Sarepta Therapeutics by 1.0% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 33,033 shares of the biotechnology company’s stock worth $4,016,000 after acquiring an additional 335 shares during the last quarter. Finally, Manchester Capital Management LLC boosted its holdings in Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares during the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Price Performance

SRPT stock opened at $105.35 on Wednesday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The business has a 50-day simple moving average of $118.57 and a two-hundred day simple moving average of $124.07. The company has a market capitalization of $10.06 billion, a P/E ratio of 84.28 and a beta of 0.75. Sarepta Therapeutics, Inc. has a 52-week low of $101.15 and a 52-week high of $173.25.

Insider Activity

In related news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now directly owns 22,840 shares of the company’s stock, valued at $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SRPT. StockNews.com lowered shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Guggenheim lifted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. HC Wainwright reaffirmed a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research report on Thursday, February 13th. Robert W. Baird lowered their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, Evercore ISI cut their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $176.77.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.